Pepco Holdings Trading Halted Due to Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Should l Buy POM?
Pepco Holdings, Inc. trading halted, volatility trading pause
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy POM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on POM
About POM
PomDoctor Ltd is a holding company principally engaged in operating a online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment mainly engaged in providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment mainly engaged in pharmacy retail sales and wholesale. The Company mainly operates its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomdoctor Investors Encouraged to Seek Legal Rights Amid Significant Losses
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Pomdoctor Limited and reminds investors to apply by April 13, 2026, to become lead plaintiffs in a federal securities class action to protect their legal rights.
- Stock Price Plunge: Pomdoctor's share price significantly dropped from approximately $0.50 to about $0.38 between December 10 and 11, 2025, representing a 24% decline in a single trading session, reflecting investor concerns regarding the company's financial performance.
- False Promotion Allegations: The lawsuit alleges that Pomdoctor and its executives violated federal securities laws through false statements and undisclosed stock manipulation activities, misleading investors about the company's prospects and affecting the stock's fair valuation.
- Investor Rights Protection: Faruqi & Faruqi encourages anyone with information regarding Pomdoctor's conduct, including whistleblowers and former employees, to contact the firm to provide support and legal assistance for affected investors.
See More
Reminder of Class Action for PomDoctor Securities Purchasers
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which led to investor losses during inflated price periods.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and extensive experience in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights in the litigation and avoid inexperienced intermediaries.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ:POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation through the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, involving fraudulent stock promotions and insider trading through offshore accounts, which significantly harmed investors.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its strong track record in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with proven success, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the litigation process.
See More
PomDoctor Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against PomDoctor, seeking damages for investors who purchased securities between October 9 and December 11, 2025, indicating strong investor concern over potential fraud.
- False Statement Allegations: The complaint alleges that PomDoctor failed to disclose significant adverse facts regarding its business and trading activities during the class period, misleading investors and affecting their assessment of the company's prospects.
- Insider Trading Issues: The lawsuit mentions that insiders used offshore accounts to facilitate stock dumping amid a fraudulent promotion scheme involving social media misinformation, highlighting serious governance failures within the company.
- Investor Rights Protection: Investors have until April 6, 2026, to request lead plaintiff status, with Bronstein, Gewirtz & Grossman, LLC offering contingency fee representation, emphasizing the importance of protecting investor rights and the need for legal support.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to protect their rights in the ongoing class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, involving fraudulent stock promotions and insider trading through offshore accounts, resulting in significant investor losses and highlighting serious governance and transparency issues within the company.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovering hundreds of millions for investors, demonstrating its expertise and resource advantages in handling such cases.
See More
Investigation Launched into Pomdoctor Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating Pomdoctor Limited for potential securities litigation due to allegations of false and misleading statements made between October and December 2025, which may have caused investor losses.
- Stock Price Plunge: Pomdoctor's share price fell from approximately $0.50 on December 10, 2025, to about $0.38 on December 11, representing a 24% decline in a single trading session, reflecting market concerns over its financial performance.
- Class Action Deadline: Investors must apply by April 6, 2026, to serve as lead plaintiffs in the federal securities class action lawsuit, allowing them to represent other affected investors in the litigation.
- Disclosure Failures: The lawsuit alleges that Pomdoctor failed to disclose false information and insider trading related to stock price manipulation, leading to investor misconceptions about the company's prospects, which could impact its future legal liabilities.
See More
Pomdoctor Investors Encouraged to Seek Legal Rights Amid Significant Losses
- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Pomdoctor Limited and reminds investors to apply by April 13, 2026, to become lead plaintiffs in a federal securities class action to protect their legal rights.
- Stock Price Plunge: Pomdoctor's share price significantly dropped from approximately $0.50 to about $0.38 between December 10 and 11, 2025, representing a 24% decline in a single trading session, reflecting investor concerns regarding the company's financial performance.
- False Promotion Allegations: The lawsuit alleges that Pomdoctor and its executives violated federal securities laws through false statements and undisclosed stock manipulation activities, misleading investors about the company's prospects and affecting the stock's fair valuation.
- Investor Rights Protection: Faruqi & Faruqi encourages anyone with information regarding Pomdoctor's conduct, including whistleblowers and former employees, to contact the firm to provide support and legal assistance for affected investors.
See More
Reminder of Class Action for PomDoctor Securities Purchasers
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which led to investor losses during inflated price periods.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and extensive experience in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights in the litigation and avoid inexperienced intermediaries.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ:POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation through the class action lawsuit.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, involving fraudulent stock promotions and insider trading through offshore accounts, which significantly harmed investors.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its strong track record in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with proven success, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the litigation process.
See More
PomDoctor Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against PomDoctor, seeking damages for investors who purchased securities between October 9 and December 11, 2025, indicating strong investor concern over potential fraud.
- False Statement Allegations: The complaint alleges that PomDoctor failed to disclose significant adverse facts regarding its business and trading activities during the class period, misleading investors and affecting their assessment of the company's prospects.
- Insider Trading Issues: The lawsuit mentions that insiders used offshore accounts to facilitate stock dumping amid a fraudulent promotion scheme involving social media misinformation, highlighting serious governance failures within the company.
- Investor Rights Protection: Investors have until April 6, 2026, to request lead plaintiff status, with Bronstein, Gewirtz & Grossman, LLC offering contingency fee representation, emphasizing the importance of protecting investor rights and the need for legal support.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to protect their rights in the ongoing class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, involving fraudulent stock promotions and insider trading through offshore accounts, resulting in significant investor losses and highlighting serious governance and transparency issues within the company.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovering hundreds of millions for investors, demonstrating its expertise and resource advantages in handling such cases.
See More
Investigation Launched into Pomdoctor Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating Pomdoctor Limited for potential securities litigation due to allegations of false and misleading statements made between October and December 2025, which may have caused investor losses.
- Stock Price Plunge: Pomdoctor's share price fell from approximately $0.50 on December 10, 2025, to about $0.38 on December 11, representing a 24% decline in a single trading session, reflecting market concerns over its financial performance.
- Class Action Deadline: Investors must apply by April 6, 2026, to serve as lead plaintiffs in the federal securities class action lawsuit, allowing them to represent other affected investors in the litigation.
- Disclosure Failures: The lawsuit alleges that Pomdoctor failed to disclose false information and insider trading related to stock price manipulation, leading to investor misconceptions about the company's prospects, which could impact its future legal liabilities.
See More
